Paxlovid for Treatment of COVID-19

Date: January 24, 2022 Issue #: 1642Summary: On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid– Pfizer) for oral treatment of mild to moderate COVID-19 in outpatients≥12 years old who weigh at least 40 kg and are at high risk of progressing to severe disease, including hospitalization or death.Paxlovid was the first oral antiviral drug to be authorized in the US for treatment of COVID-19; Merck ' s oral antiviral drug molnupiravir was granted an EUA for treatment of COVID-19 on December 23, 2021. The IV antiviral drug remdesivir(Veklury) was approved by the FDA in 2020 for treatment of COVID-19 in hospitalized patients.

http://secure.medicalletter.org/TML-article-1642a

Source: The Medical Letter - January 7, 2022 Category: Drugs & Pharmacology Authors: admin Tags: Antiviral drugs COVID-19 molnupiravir nirmatrelvir Paxlovid remdesivir Ritonavir Veklury Source Type: research